Abstract
Purpose The Vascular, Extracellular and Restricted Diffusion for Cytometry in Tumours (VERDICT) technique has shown promise discriminating normal from prostate cancer (PCa) tissue and Gleason grade 3+3 from 3+4. However, VERDICT currently doesn’t account for the inherent relaxation properties of the tissue that could add complementary information and potentially enhance its diagnostic power. The aim of this work is to introduce relaxation-VERDICT (rVERDICT) for prostate, a model for the joint estimation of diffusion and relaxation parameters.
Methods 72 men with suspected PCa underwent multiparametric MRI (mp-MRI) and VERDICT MRI. Among these, 44 underwent targeted biopsy and were analysed with rVERDICT using deep neural networks for fast fitting (∼60 times faster than non-linear least squares minimisation approach). A convolutional neural network classifier assessed the rVERDICT parameters in differentiating Gleason grades measured with accuracy, F1-score and Cohen’s kappa. To assess repeatability, five men were imaged twice.
Results There were 37 cancer lesions: 6 Gleason 3+3, 18 Gleason 3+4, and 13 Gleason ≥4+3. The rVERDICT intracellular volume fraction fic discriminated between Gleason 3+3 and 3+4 (p=0.003); Gleason 3+4 and ≥4+3 (p=0.040); and between 5-class Gleason grades with (accuracy, F1-score,kappa)=(8,7,3) percentage points higher than classic VERDICT, and (12,13,24) percentage points higher than the ADC from mp-MRI. Repeatability of rVERDICT parameters was high (R2=0.79–0.98,CV=1%–7%,ICC=92%-98%). T2 values estimated with rVERDICT were not significantly different from those estimated with an independent multi-TE acquisition (p>0.05).
Conclusion rVERDICT allows for accurate, fast and repeatable estimation of diffusion and relaxation properties of PCa and enables discriminating Gleason grade groups.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02689271
Funding Statement
This work was supported by EP/N021967/1, EP/R006032/1 and by Prostate Cancer UK: Targeted Call 2014: Translational Research St.2, project reference PG14-018-TR2. M.P. is supported by the UKRI Future Leaders Fellowship MR/T020296/2.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the study was granted by the London-Surrey Borders Research Ethics Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Text, Tables and Figures have been updated after first major revision from submission to Magnetic Resonance in Medicine. Further analysis and numerical simulations have been performed on the same data. No new data have been collected nor processed/analysed.
Data Availability
Data were collected within the INNOVATE clinical trial, registered with ClinicalTrials.gov identifier NCT02689271 and they are not publicly available.
